Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 23, 2026
NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.
Journal: Endocrine-related cancer
Published: September 05, 2025
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Journal: Frontiers in oncology
Published: August 20, 2024
Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.
Journal: Pediatric blood & cancer
Published: December 19, 2023
Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 17, 2023
Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 27, 2023
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
Journal: Journal of nuclear medicine technology
Published: September 10, 2022
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.
Journal: Cancers
Published: March 16, 2022
Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 15, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 05, 2021
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Journal: The Lancet. Oncology
Published: March 10, 2021
Last Updated: 09/26/2026